<DOC>
	<DOCNO>NCT00559585</DOCNO>
	<brief_summary>The purpose study determine whether weekly subcutaneous dose abatacept yield clinical efficacy comparable monthly intravenous dos abatacept participant rheumatoid arthritis inadequate response current methotrexate therapy .</brief_summary>
	<brief_title>Methotrexate-Inadequate Response Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects consider methotrexate inadequate responder 10 swollen joint ( 66 joint count ) 12 tender joint ( 68 joint count ) Subjects failed one multiple antitumor necrosis factor ( TNF ) therapies Subjects meet diagnostic criterion rheumatic disease ( e.g. , lupus erythematous ) Subjects active vasculitis major organ system ( except subcutaneous rheumatoid nodule ) Subjects severe chronic recurrent bacterial infection Subjects receive treatment rituximab An AntiTNF Failure Substudy initiate ( recruit separately Main study ) use treatment Main study order ass immunogenicity safety AntiTNF Failure population . The Substudy terminate due low recruitment participant permit roll LT Open Label Period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>